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Background: The aim of this study is to determine the risk of cancer in patients with primary Sjögren syndrome (pSS) from a single
center in Turkey.
Methods: Clinical data of the subjects with pSS were retrospectively analyzed. The incidence of cancer for general population was
obtained from GLOBOCAN 2018. Age- and sex-specific standardized incidence ratios (SIR) of solid and hematological cancers were
calculated compared with the general population.
Results: Four hundred thirty patients with pSS were included in the study. The majority of the patients were female (n = 396, 92.1%),
and the mean age was 58.6 ± 12.0 years. Thirty-four patients (7.9 %) were diagnosed with cancer (26 solid and 8 hematological) during
follow-up. The SIR for all cancers was 2.45 (95% CI, 1.625–3.275). The SIR was 2.42 (95% CI, 1.542–3.298) for solid cancers and 8.42
(95% CI, 2.394 - 14.446) for hematological cancers. The most diagnosed malignancies were breast cancer (n = 6), ovarian cancer (n = 6),
and non-Hodgkin lymphoma (NHL) (n = 4). There was an increased risk for ovarian cancer (SIR 12.76, 95% CI, 2.545–22.975). The SIR
values were 2.08 (95% CI, 0.419-3.741) and 10.81 (95% CI, 0.216–21.404) for breast cancer and NHL, respectively.
Conclusion: The risk of hematological and solid cancers was higher in the patients with pSS when compared to general population. In
our pSS cohort, the risk for ovarian cancer was found to be increased, which has not been previously reported in the literature.
Key words: Sjögren syndrome, cancer, lymphoma, incidence, malignancy

1. Introduction
Primary Sjögren syndrome (pSS) is a systemic autoimmune
disease that mainly affects secretory glands [1]. Most
patients with pSS suffer from dryness of mouth and eyes.
Some patients have systemic diseases involving skin,
joints, lungs, nervous system, muscles, and hematopoietic
system [2–4]. Primary SS is characterized by lymphocytic
infiltration of affected tissues. Lymphoid aggregates
and ectopic lymphoid structures containing T and B
lymphocytes develop in response to chronic inflammation
in nonlymphoid organs. Antigen-driven T cell-mediated
B cell hyperreactivity, leading to autoreactive B cell
activation, plays an important role in the pathogenesis of
pSS [5, 6].
Clinical studies to clarify whether the survival of the
patients with pSS is similar to the general population are
in progress. The prognosis varies depending on disease
severity, extent, and comorbidities. Systemic organ
involvements and malignancies, including lymphoma, may

contribute to an increase in mortality rates. Our clinical
data revealed that the mortality rate of the patients with
pSS was higher than that of the general population, the
patients with interstitial lung disease had lower survival
rates, and malignancy may also be associated with a worse
prognosis [7].
It is known that the risk of lymphoma and solid
organ cancers is increased in patients with pSS [8–10].
Many clinical studies showing increased non-Hodgkin
lymphoma (NHL) prevalence in pSS have already been
published [11–13]. In a metaanalysis, it was found that the
frequency of developing lymphoma at 5, 15, 20 years after
the diagnosis were 4%, 10%, and 18%, respectively [14].
The rate of malignancy among patients with pSS during an
18-year follow-up in Sweden was 11.5% [15]. On the other
hand, malignancy was diagnosed in 2.2% of a Chinese pSS
cohort during 15-year follow-up [8]. Primary SS is also
associated with the development of solid cancers. In the
literature, there are clinical studies reporting enhanced
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risk for the development of thyroid, oral cavity, and
stomach cancers, while a lower risk for colon and breast
cancers [16, 17, 18].
The frequency of malignant diseases may be different
among populations depending on the genetic and
environmental factors [19]. The development of cancers is
affected by the differences in sex, age, ethnicity, diet and
environmental exposures, and also chronic diseases. The
predictive factors for the development of lymphoma in
pSS are the presence of glandular enlargement, cutaneous
vasculitis,
glomerulonephritis,
cryoglobulinemia,
lymphadenopathy, neutropenia, splenomegaly, and
hypocomplementemia [20–22]. The risk factors and
predictors for the development of solid cancers in pSS
are not clear as in hematologic malignancies. In addition,
there is no published report concerning the frequency and
risk factors for malignancy in Turkish patients with pSS.
The aim of this study was to determine the risk of cancer
in a Turkish pSS cohort from a single-center.
2. Materials and methods
2.1. Study population
Patients who were diagnosed with pSS according to
American College of Rheumatology 2012 criteria at
Akdeniz University Hospital between January 2004 and
December 2018 were included in the study [23]. Patients
who had other rheumatic diseases, in addition to pSS,
were excluded. The clinical characteristics and laboratory
findings of the patients were retrospectively collected
from their medical records and the hospital’s electronic
database.
Histopathologically detected cancers were determined
and classified according to the International Classification
of Diseases (ICD 10) criteria, and cancers developed after
the diagnosis of pSS were included in the analysis.
2.2. Patient variables
Clinical variables such as age, sex, disease duration,
and follow-up period of the patients were analyzed. In
addition, the presence of dry eyes or dry mouth, joint
symptoms/findings, Raynaud phenomenon, and lung
involvement were recorded. Laboratory findings including
complete blood counts, biochemical tests, erythrocyte
sedimentation rate (ESR), C-reactive protein (CRP),
antinuclear antibodies (ANA), rheumatoid factor (RF),
anti-ro and anti-La antibodies, complement 3 (C3),
complement 4 (C4), and immunoglobulin levels were
recorded after review of electronic medical records.
Normal laboratory values were defined according to our
laboratory reference values. Anemia, leukopenia, and
thrombocytopenia were defined as hemoglobin level less
than 12 mg/dL, a leukocyte count less than 4.0x109/L, and
a thrombocyte count less than 100x 109/L. If ESR and CRP
values were over 20 mm/h and 0.5 mg/dL, respectively,
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they were considered as high. The cut-off value for ANA
positivity was considered as > 1/100 titer. The presence of
anti-Ro/anti-La antibodies was determined by extractable
nuclear antigen panel, and RF positivity was determined
by nephelometric test method. Cut-off levels for C3 and C4
were 80 mg/dL and 10 mg/dL, respectively.
This study was approved by the medical ethics
committee of Akdeniz University Hospital and complied
with the principles of the Declaration of Helsinki.
2.3. Statistical analysis
Statistical analyses were performed using SPSS software,
version 13.0 (SPSS, Chicago, IL, USA). The data were
expressed as means ± standard deviation (SD) for
continuous variables. Continuous variables were compared
using the Student’s t-test. Categorical variables were
compared using a chi-square test. Logistic regression
analyses were used to determine the risk factors associated
with the development of malignancy. A value of p < 0.05
was considered significant.
The person-years of follow-up for patients with pSS
were calculated from the date of diagnosis to the last visit
or cancer diagnosis (whichever occurred earliest). Cancer
data of the Turkish population were determined from
GLOBOCAN 2018 [24]. The standardized incidence ratios
(SIR), also stratified by sex and age, were computed as the
ratio of observed to expected cancers in the patients with
pSS. The 95% confidence intervals (CI) of the SIR were
also calculated. The incidence of cancer for the Turkish
population was obtained from GLOBOCAN 2018. There
were no patients diagnosed with pSS under 20 years old in
this study group, so, age- (over 20 years old) and genderspecific standardized incidence ratios (SIR) were calculated.
The incidence of cancer for the Turkish population older
than 20 years was reported to be 363/100.000 (460/100.000
for males, 292/100.000 for females) in GLOBOCAN 2018
Turkey database.
3. Results
3.1. Characteristics of the subjects
There were 430 patients with pSS who were older than 18
years and diagnosed between the years 2004-2018 (Table
1). The mean age of the patients was 58.6 ± 12.0 years (MinMax: 21-80 years). The majority of patients were female (n
= 396, 92.1%). During follow-up period, 34 patients (7.9%)
were diagnosed with malignant disease, of which 26 were
solid tumors, and 8 were hematological cancers. The most
frequent types of cancers were breast (1.4%) and ovarian
(1.4%) cancers. All hematological cancers were seen in
female patients. The results demonstrated the prevalence
of malignancy was higher in male than female patients
(11.8% versus 7.6%). But it was not statistically significant
(p: 0.330). The types of cancers detected and their
distribution among patients are shown in detail in Table 2.
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Table 1. Comparison of the characteristics of pSS patients with and without cancer.
pSS patients

All patients

without cancer

with cancer

p

n

430

396

34

Age, years, (mean±SD)

58.3±12.0

57.9±12.0

66.2±10.2

< 0.001

Duration of disease, (mean±SD)

7.41±4.7

7.25±4.6

9.30±5.2

0.003

n/n

%

n/n

%

n/n

%

Female

396/430

92.1

366/396

92.4

30/34

88.2

0.385

Dry mouth

413/430

96.0

380/396

69.0

33/34

97.1

0.768

Dry eyes

378/430

87.9

346/396

87.4

32/34

94.1

0.856

Focus score ≥ 1

256/303

85.0

232/276

84.1

24/27

88.8

0.756

ANA (>1/100 dilution) (+)

267/425

62.8

247/391

63.2

20/34

58.8

0.615

Anti-Ro (+)

181/377

48.0

166/346

47.9

15/31

48.4

0.341

Anti-La (+)

51/402

12.7

45/371

12.1

6/31

19.4

0.246

Rheumatoid factor (+)

79/342

23.1

69/308

22.4

10/34

29.4

0.210

Anemia

107/373

28.7

97/340

28.5

10/33

30.3

0.491

Leukopenia

66/425

15.5

57/392

14.5

9/33

27.3

0.052

Lymphocytopenia

61/397

15.4

54/368

14.7

7/29

24.1

0.174

Thrombocytopenia

21/424

5.0

15/391

3.8

6/33

18.2

<0.001

Hypergammaglobulinemia

70/289

24.2

65/264

24.6

5/25

20.0

0.775

Low C3/C4

33/357

9.2

28/330

8.5

5/27

18.5

0.084

Arthralgia and/or arthritis

236/373

63.3

217/343

63.3

19/30

63.3

0.994

Raynaud’s phenomenon

44/360

12.2

39/332

11.7

5/28

17.9

0.379

Pulmonary involvement

63/381

16.5

57/349

16.3

6/32

18.8

0.725

Elevated ESR (at the diagnosis)

225/376

59.8

209/351

59.5

16/25

64.0

0.661

Elevated CRP (at the diagnosis)

134/377

35.5

120/352

34.1

14/25

56.0

0.027

Use of corticosteroids

106/387

27.4

94/360

26.1

12/27

44.5

0.039

Use of hydroxychloroquine

345/375

92.0

32/349

91.7

24/26

92.3

0.952

At least one immunosuppressant*

100/363

27.5

88/336

26.2

12/27

44.4

0.041

pSS, primary Sjögren syndrome; n, number of patients; SD, standard deviation; ANA, antinuclear antibodies; C3, complement 3; C4,
complement 4; ESR, Erythrocyte sedimentation rate; CRP, C-reactive protein; *include azatiopürine, methotrexate, rituximab and
cyclophosphamide

The clinical characteristics and laboratory data of
the patients with and without cancer were compared
(Table 1). The patients with cancer were older (66.2
±10.2 vs. 57.9±12.0 years, p < 0.001) and their disease
duration was longer (9.30±5.2 vs. 7.25±4.6 years, p =
0.003) than the subjects with no cancer. The incidence
of thrombocytopenia and increased CRP levels detected
at the time of diagnosis were significantly higher in the
patients with cancer when compared to the subjects with
no cancer (18.2% vs. 3.8%, p < 0.001, and 56% vs. 34.1%, p
= 0.027, respectively).

3.2.Standardized incidence ratios (SIRs) for cancer
The rates of cancer incidence for this cohort and Turkish
population in general, both expressed as 100,000 patientyears, were given in Table 3. The SIR was calculated by using
the observed and expected number of patients, and it’s 95%
CI. The SIR (95% CI) could not be calculated for cancer
subtypes less than four. Therefore, the SIRs were given for
all cancers, solid/hematological, and the most commonly
seen types (breast, ovarian, and non-Hodgkin lymphomas).
Compared with the general population, the SIR was
2.45 (95% CI 1.625–3.275) for all cancers and was higher
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Table 2. The distribution of cancers in pSS patients.
pSS cohort
Overall
(n = 430)

Female
(n = 396)

Male
(n = 34)

p

All cancers (n, %)

34 (7.9%)

30 (7.6%)

4 (11.8%)

0.330

Solid cancers (n, %)

0.147

26 (6.0%)

22 (5.6%)

4 (11.8%)

Breast (n)

6

6

-

Ovarian (n)

6

6

-

Lung (n)

2

2

-

Thyroid (n)

2

2

-

Pancreas (n)

2

-

2

Stomach (n)

2

1

1

Skin (n)

1

1

-

Colorectal (n)

1

-

1

Corpus uteri (n)

1

1

-

Bladder (n)

1

1

-

Brain (n)

1

1

-

Renal cell (n)

1

1

-

Hematological (n, %)

8 (1.8%)

8 (2.0%)

-

NHL (n)

4

4

-

Leukemia (n)

3

3

-

MM/ID (n)

1

1

-

1.000

pSS, primary Sjögren syndrome; NHL, Non-Hodgkin lymphoma; MM/ID, myeloma multiple and malignant
immunoproliferative diseases.

in men than in women (2.96 vs. 2.91) (Table 3). The SIR
was 2.42 (95% CI 1.542–3.298) for solid cancers and
8.42 (95% CI 2.394–14.446) for hematological cancers.
Concerning the types of cancer, there was an increased
risk for ovarian cancers (SIR 12.76; 95% CI 2.545–22.975).
The SIRs were 2.08 (95% CI 0.419–3.741) and 10.81 (95%
CI 0.216–21.404) for breast cancer and NHL, respectively.
The logistic regression analysis indicated that older
age (p = 0.005), presence of leukopenia (p = 0.30) and
thrombocytopenia (p < 0.01), and use of corticosteroids
(p < 0.01) were independent risk factors of developing
malignancies in pSS patients (Table 4).
4. Discussion
This study was conducted to determine the risk of cancer
in patients with pSS. The results revealed that the overall
cancer incidence rates, both for solid and hematologic
cancers, were higher in the patients with pSS when
compared to age and gender-matched populations. There
was a 2.45-fold overall increased risk for cancer (SIR:
2.45, 95% CI 1.625–3.275). This study is the first report
on the risk of cancer and cancer types detected in Turkish
patients with pSS.
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Although it is already known that the incidence of
cancers, especially lymphomas, is increased in the patients
with pSS, the exact rates are unknown. Igoe et al. reported
that the patients with pSS had a greater risk for developing
lymphoma (SIR, 10.5–44), multiple myeloma (SIR, 3.3–
1.5), and lung cancer (SIR,1.29–4.5) when compared
to healthy individuals [25]. The risk of NHL in pSS was
higher than that reported for patients with systemic lupus
erythematosus (SLE) and rheumatoid arthritis (RA)
[25]. In a metaanalysis, Liang Y et al. reported an overall
increased risk for cancers, NHL, and thyroid cancer in
pSS, and stated that it has not yet been known whether the
increased risk of overall malignancy was due to relatively
high prevalence of NHL [9]. Some authors have suggested
the increased overall cancer risk was associated with
hematological cancers [26]. There is a debate as to whether
the risk of developing solid cancers is increased in pSS. In
addition, an increase in the incidence of nonhematological
malignancies has not been proven in some studies [15, 22].
Our findings confirmed an increased risk of solid cancers
in patients with pSS. The SIR was calculated as 2.42 (95%
CI 1.542–3.298) for solid cancers detected in our pSS
cohort. Our findings were consistent with the results of

9.6

4

8

6

6

25

34

0.37

0.92

0.47

2.89

10.81 (0.216–21.404)

8.2

20.2
4

8

6

8.42 (2.394–14.446)

6

21

30

75.9

254.2

292.8

0.29 13.79 (0.276–22.310)

0.71 11.27(3.462–19.078)

0.43 13.95 (2.785–25.115)

2.67 2.25 (0.452–4.048)

8.95 2.35 (1.347–3.353)

10.31 2.91 (1.869–3.951)

Obs Exp* SIR (95% CI)

pSS cohort

12.76 (2.545–22.975) 12.3

2.08 (0.419–3.741)

11.15 2.42 (1.542–3.298)

13.85 2.45 (1.625–3.275)

SIR (95% CI)

Incidence in the
Turkish women
population

Women (n = 396)

11.2

28.8

-

-

398.8

460.9

Incidence
in the
Turkish men
population

Men (n = 34)

-

-

-

-

4

4

-

-

3.39 (0.068–6.712)

2.96 (0.056–5.864)

0.03

-

0.08 -

-

-

1.18

1.35

Obs Exp* SIR (95% CI)

pSS cohort

Obs, observed; Exp, expected; SIR, standardized incidence ratio; CI, confidence interval; NHL, Non-Hodgkin lymphoma
*Calculated using data from GLOBOCAN 2018 (Global Cancer Observatory, International Agency for Research on Cancer, World Health Organization Cancer Today. https://gco.
iarc.fr/) for +20 years olds.
Obs, observed; Exp, expected; SIR, standardized incidence ratio; CI, confidence interval; NHL, Non-Hodgkin lymphoma
*Calculated using data from GLOBOCAN 2018 (Global Cancer Observatory, International Agency for Research on Cancer, World Health Organization Cancer Today. https://gco.
iarc.fr/) for +20 years olds.

NHL

24.1

12.3

Hematological

75.9

Ovarian

292.3

Breast

363.2

Solid cancers

Incidence in pSS cohort
the general
Turkish
population Obs Exp*

All cancers

Cancer
Categories

Total (n = 430)

Table 3. Standardized incidence ratios (SIRs) for cancers in pSS patients.
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Table 4. Logistic regression analysis of the risk factors for cancers in pSS patients.
B

t

95% Convidence Interval p

Gender

0.050

0.769

–0.094

0.215

0.443

Age

0.191

2.837

0.001

0.008

0.005

Disease duratiom

0.139

1.916

0.000

0.019

0.057

Antinuclear antibodies (+)

–0.021

–0.336

–0.055

0.039

0.737

Rheumatoid factor (+)

–0.024

–0.384

–0.025

0.017

0.701

Anti-Ro (+)

–0.015

–0.215

–0.015

0.012

0.830

Anemia

–0.026

–0.391

–0.103

0.069

0.696

Leucopenia

0.143

2.181

0.010

0.205

0.030

Thrombocytopenia

0.236

3.596

0.128

0.440

<0.001

Low complement levels

0.090

1.348

–0.037

0.198

0.179

Raynaud’s phenomenon

0.000

0.000

–0.113

0.113

1.000

Hypergammaglobulinemia

–0.082

–1.273

–0.119

0.026

0.205

Pulmonary involvement

–0.009

–0.139

–0.106

0.092

0.889

Use of corticosteroids

0.333

4.008

0.002

0.006

<0.001

Use of hydroxychloroquine

0.001

0.008

–0.002

0.002

0.993

Use of immunosuppressant

–0.147

–1.896

–0.003

0.000

0.059

recently published studies that revealed a high risk for
solid cancers [10,27].
Lymphocytic infiltration in target tissues and chronic
lymphocyte activation are key features of pSS. B cellactivating factor (BAFF), cytokines, activation of NfkB, and germinal center-like (GC-like) structures are
important for the development of lymphoma in pSS
[28]. Our results show that Turkish patients with pSS
have lower risk for developing NHL (SIR: 10.81, 95%
CI 0.216–21.404) when compared to Chinese (SIR:48.1,
95% CI 20.7–94.8), Argentine (SIR:41.40, 95% CI 10.12–
102.1) Swedish (SIR:15.57, 95% CI 7.8–27.9), and British
(SIR:37.5, 95% CI 20.7–67.6) patients [8,10,15,22], while
it washigher than Spanish (SIR:6.04, 95% CI 3.43–10.64),
Korean (SIR:6.42, 95% CI 4.09-8.76), and Finn (SIR:8.7,
95% CI 4.3–15.5) patients with pSS [16,27,29]. The main
reason for not detecting statistical difference for NHL in
this study is the small number of patients diagnosed with
NHL.
The current evidence about the development of NHL
in pSS is increasingly growing. The clinical and laboratory
predictors, such as the presence of salivary gland
enlargement, lymphadenopathy, Raynaud phenomenon,
anti-Ro/SSA
or/and
anti-La/SSB
autoantibodies,
RF
positivity,
monoclonal
gammopathy,
and
hypocomplementemia were identified to be independent
predictors for the development of NHL [30]. The reason
why the risk is different for different populations with pSS
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is another issue that needs to be investigated. It can be
explained by international, multicenter registries covering
a large number of cases. A multinational study showed
that the systemic phenotype of pSS was influenced by
geoepidemiological players and personal determinants
such as age, gender, ethnicity, and place of residence [31]. In
this study, we analyzed the risk factors for the development
of all cancers, not only NHL. Older age, leukopenia and
thrombocytopenia, and use of corticosteroids were related
to the development of malignancies.
In contrast to hematologic malignancies, data on solid
cancers seen in the subjects with pSS are not consistent.
There are incompatible data in the literature regarding
solid tumors and their incidence in patients with pSS.
Some studies revealed a high incidence of several organspecific malignancies such as thyroid, breast, lung, oral
cavity, and stomach cancers. A recently published study
showed an elevated risk for oropharyngeal cancer, as well
as lung cancer in males, and thyroid cancer in female
patients [27]. Another study revealed an increased risk for
the development of thyroid, lip, oral cavity, and stomach
cancers [16]. In a metaanalysis, it was reported that only
the risk for developing thyroid cancer was increased
among solid tumors, and the SIR was found to be 0.61
(95% CI 0–1.21) for ovarian cancer [9]. Brito-Zerón P et
al. did not detect an increased risk for ovarian (SIR; 0.46,
95% CI 0.07–3.28) and breast (SIR; 0.89, 95% CI 0.53–1.51)
cancers [16]. In this study, the most common solid cancers
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were breast (n = 6) and ovarian cancers (n = 6), and there
was a significant relationship between pSS and the risk of
ovarian cancer (SIR 12.76; 95% CI 2.545–22.975).
There is an increased risk for the development of
hematological malignancies in autoimmune diseases,
which provide a perfect environment for tumor
development via loss of self-tolerance and chronic immune
dysregulation [32]. The immunopathogenetic pathways of
pSS overlap with SLE and two diseases may occur together
[33]. SLE is also associated with the overall increased
cancer risk -a 4-fold increased risk for NHL- compared
with the general population. The potential mechanisms
for the development of malignancy are dysfunctions of
the immune system, cytokines, and other pathways [34].
The risk of developing hematological cancers in patients
with pSS and SLE is higher, and they may develop through
common pathogenesis in both disorders. A decreased
risk for breast, ovarian, and endometrial cancers was
reported in the subjects with SLE [35]. It was claimed that
this risk reduction might be related to hormonal factors
or lupus-related antibodies [34]. Breast cancer is among
the most commonly encountered cancers in patients
with systemic sclerosis and inflammatory myopathies
[36,37]. Like SLE, the risk of breast cancer is reduced
in RA [38]. The risk for ovarian cancer is also increased
in patients with inflammatory myopathies [36]. In the
light of this information, it can be concluded that, unlike
hematological cancers, the development of solid cancers
can be associated with different factors and mechanisms
underlying the pathogenesis of autoimmune diseases.
Ovarian cancer risk increases with older ages, and it is
more prevalent in western countries. It can be related to
reproductive period, the number of births, breastfeeding,
genetics, and environmental factors such as diet [39].
Chronic inflammation could be associated with an
increased risk of ovarian cancer via cyclo-oxidase enzyme,
arachidonic acid, and prostaglandins as well as increased
estrogen levels. Regular acetylsalicylic acid intake is
associated with the reduction in ovarian cancer risk [40].
Regular exercise reduces the risk of cancers, including
ovarian cancer [41]. Hormonal contraception in any
period of life reduces the risk of developing ovarian cancer
[42]. In this study, we did not investigate the causes of solid
cancers, including ovarian cancer. In addition to known
risk factors, chronic inflammation, inactivity due to joint
problems, and avoidance of hormonal contraception in the
patients with pSS may contribute to the increased risk of
ovarian cancer. Further studies are necessary to determine
pSS-related risk factors for ovarian cancer.

There are some limitations of this study; first, the
limited number of patients made statistical analysis
difficult. Especially, the number of male patients with pSS
was low in this cohort. It was impossible to calculate the
SIR of cancer types with less than four patients because of
the wide range of confidence intervals and the standard
error. Secondly, the study was conducted retrospectively,
therefore, data on comorbidities known to be associated
with cancers such as smoking and drinking habits, physical
activity, and disease activity could not be collected and
analyzed. Thirdly, since disease activity for pSS could not be
calculated for all patients, the relationship between disease
severity and cancers could not be examined. Fourthly, due
to lack of information about regional cancer incidence in
Antalya, where the data were collected, cancer incidence
in the general population was obtained from GLOBOCAN
2018 Turkey database. Nevertheless, since this study was
conducted in a wide region of Turkey with 2.5 million
people, the results may reflect the situation of the Turkish
population with pSS.
In conclusion, data on the development of solid
and hematological malignancies in our pSS cohort are
presented in this article. The prevalence of malignancy in
the patients with pSS was found to be 7.9%, and the overall
cancer risk was found to increased by 2.45-fold. The risk
for the development of ovarian cancer was significantly
increased in the subjects with pSS. Further studies are
required to reveal pSS-related factors playing a role in the
development of ovarian cancer.
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